aripiprazole: the legal and safety record

The regulator moved first

In May 2016, the FDA warned that aripiprazole is associated with compulsive or uncontrollable urges — to gamble, binge eat, shop, and have sex — and required label warnings. The detail that gives the signal its weight: the reported urges stopped when the drug was stopped or the dose reduced [1]. An on/off pattern is what turns case reports into a warning, and that regulatory finding — not any verdict — is the evidence-grade core of this record.

Then the courts, in two tracks

The injury track: roughly 2,000 compulsive-behavior cases consolidated as MDL 2734 in the Northern District of Florida from October 2016, resolved by a confidential master settlement dated February 15, 2019 — a date and scope stated in Bristol Myers Squibb’s own SEC filings [2]. Confidential means adjudicated nothing; no court ruled on causation for anyone. The marketing track: in December 2016, 43 attorneys general settled for $19.5 million over promotion of Abilify to children and to elderly patients with dementia and minimization of risks — allegations resolved, no admission [3].

One circle this page refuses to complete: gambling terms are prominent in aripiprazole’s public adverse-event reports, and years of lawsuit advertising are part of why. Report counts are not evidence the claims were true, which is exactly why our aripiprazole page prints the reporting system’s limits above its numbers.

What is not in the record

• No adjudicated causation finding — the MDL settled confidentially before any bellwether verdict resolved the question [2].
• No federal criminal case over Abilify marketing; the state AG matter was civil consumer-protection [3]. (BMS’s 2007 federal settlement predates this story and involved different conduct.)
• No Class I recall — twenty-nine records, all Class II/III [4].

Common questions

What did the FDA actually warn about Abilify?

In May 2016 the FDA issued a Drug Safety Communication stating that compulsive or uncontrollable urges — to gamble, binge eat, shop, and have sex — have been reported with aripiprazole, that the urges stopped when the drug was stopped or the dose reduced, and that labels would be updated to warn about it. That regulatory finding, not any lawsuit, is the evidence-grade core of this page.

How did the Abilify gambling lawsuits end?

In a confidential master settlement dated February 15, 2019, resolving the roughly 2,000-case federal MDL (No. 2734, Northern District of Florida) and related state cases — a date and scope stated in Bristol Myers Squibb’s own SEC filings. Confidential settlements adjudicate nothing: no court ruled that Abilify caused any individual’s gambling.

What was the $19.5 million settlement?

A separate consumer-protection matter: in December 2016, 43 attorneys general settled claims that Abilify had been marketed for unapproved uses — to children and to elderly patients with dementia — and that risks were minimized. Like most state AG settlements it resolved allegations without an admission.

Is the compulsive-behavior risk real, then?

The FDA concluded the association was real enough to require a warning, and the on/off pattern — urges stopping when the drug stops — is the kind of signal regulators weight heavily. What no public number can tell you is frequency: adverse-event report counts for this drug are inflated by years of litigation advertising, which is exactly why our aripiprazole page prints the reporting system’s limits above its counts.

Should I stop aripiprazole because of this?

No — abrupt antipsychotic stops carry serious risks. The actionable version of this record is a monitoring question: if new gambling, spending, eating or sexual urges appeared after starting or increasing this drug, that is precisely the conversation the 2016 label change exists to prompt, and the on/off pattern makes it a solvable problem with a prescriber rather than a private shame.

Sources

Last verified 2026-09-01. Corrections change this date.